A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. (Q52873936)
Jump to navigation
Jump to search
scientific article published on 11 September 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. |
scientific article published on 11 September 2014 |
Statements
A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors (English)
Colin R Lindsay
Laura Goff
Jeff Sosman
Jill Gilbert
Jordan Berlin
Srinivasu Poondru
Rich Gedrich
Andrew Stephens
Emily Chan
T R Jeffry Evans
11 September 2014